Federal Register Notice: FDA has determined the regulatory review period for AstraZeneca’s Brilinta is 2,976 days for extending a patent, which claims that human drug product. FDA has approved the drug to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome. To view this notice, click here.
